New FDG Infusion System Cleared
The new Intego PET Infusion system was cleared for launch in the US by the FDA. MEDRAD, Incorporated manufactures the new FDG Infusion system used for PET/CT studies. This is the first system in the U.S. to automate FDG delivery.
The MEDRAD delivery system automates extraction of a single patient dose from a multi-dose vial. The Intego then directly administers the proper dosage to a patient. The automated system negates the need for manual efforts to prepare and deliver doses of FDG. A secondary benefit of such is reduced exposure to technologists from the radioactive substance.
Benefits of the tool include simplified and more flexible administration; clinicians can deliver therapy at any time. Specifically, dosing can be delivered on demand. This allows for scheduling changes and delays in the Nuclear Medicine Department.
The tool also improves both precision of safety in FDG delivery. Dose precision is achieved through a number of features incorporated into the tool. Those are an integrated ionization chamber, an optional calculation for weight-based dosing, and real-time information detailing availability of FDG doses.
Safety features incorporated include a mobile cart that is completely lead-lined, automation of saline flush after dose delivery to remove remaining FDG product from the patient’s catheter, and a tungsten multi-dose vial shield. The company is dedicated to the development of tools to improve delivery of agents used in PET/CT imaging.
June 18, 2008 Related topics: New Technology & Innovation, Quality, Safety, Errors, Nuclear Medicine